

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

LICENSING AGREEMENT WITH BIOTHEUS

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) is pleased to announce that on November 14, 2022, Hansoh (Shanghai) Healthtech Company Limited * (翰森(上海)健康科技有限公司) (the “**Licensee**”), a wholly-owned subsidiary of the Company, entered into a license agreement (the “**Licensing Agreement**”) with Biotheus Inc.* (“**Biotheus**”).

Pursuant to the Licensing Agreement, the Licensee obtained an exclusive license from Biotheus to develop and commercialize PM1080 within China (including Hong Kong, Macau and Taiwan). The Licensee will be responsible for the development, regulatory approval, manufacture and commercialization of PM1080 in China. In return, Biotheus will receive an upfront payment of RMB50 million and will be eligible for up to RMB1.418 billion milestone payment when the indications as specified under the Licensing Agreement reach commercialization, as well as tiered royalties calculated based on future net sales in China.

ABOUT PM1080

PM1080 is an EGFR/cMet bispecific anti-body drug with great therapeutic potential to block both EGFR and c-Met signaling, inhibit tumor growth and survival, etc. PM1080 is in pre-clinical stage currently.

ABOUT BIOTHEUS

Incorporated in 2018, Biotheus is a clinical-stage biopharmaceutical company focused on the development of innovative biologics in the areas of malignancies and autoimmune diseases. To the best knowledge and belief of the Company, Biotheus is independent of, and is not connected with, the Company and its connected person (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). The transactions contemplated under the Licensing Agreement do not constitute any notifiable transactions or connected transactions of the Company under Listing Rules.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, November 14, 2022

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* *For identification purposes only*